Impact of decreasing the proportion of higher energy foods and reducing portion sizes on food purchased in worksite cafeterias:A stepped-wedge randomised controlled trial by Reynolds, James P. et al.
Topic Item no Checklist item Page no
Title and abstract
1a Identification as a SW-CRT in the title.
1b Structured summary of trial design, methods, results, and conclusions  
(see separate SW-CRT checklist for abstracts).
Introduction
Background and  
objectives
2a Scientific background. Rationale for using a cluster design and rationale for 
using a stepped wedge design.
2b Specific objectives or hypotheses.
Methods
Trial design 3a Description and diagram of trial design including definition of cluster, number 
of sequences, number of clusters randomised to each sequence, number of 
periods, duration of time between each step, and whether the participants  
assessed in different periods are the same people, different people, or a 
mixture.
3b Important changes to methods after trial commencement (such as eligibility 
criteria), with reasons.
Participants 4a Eligibility criteria for clusters and participants.
4b Settings and locations where the data were collected.
Interventions 5 The intervention and control conditions with sufficient details to allow  
replication, including whether the intervention was  maintained or repeated, 
and whether it was delivered at the cluster level, the individual participant 
level, or both.
Outcomes 6a Completely defined prespecified primary and secondary outcome measures, 
including how and when they were assessed.
6b Any changes to trial outcomes after the trial commenced, with reasons.
Sample size 7a How sample size was determined. Method of calculation and relevant  
parameters with sufficient detail so the calculation can be replicated.  
Assumptions made about correlations between outcomes of participants  
from the same cluster. (see separate checklist for SW-CRT sample size items).





8a Method used to generate the random allocation to the sequences of  
treatments.





9 Specification that allocation was based on clusters; description of any  
methods used to conceal the allocation from the clusters until after  
recruitment.
Implementation 10a Who generated the randomisation schedule, who enrolled clusters, and  
who assigned clusters to sequences.
10b Mechanism by which individual participants were included in clusters  
for the purposes of the trial (such as complete enumeration, random  
sampling; continuous recruitment or ascertainment; or recruitment at a  
fixed point in time), including who recruited or identified participants.
10c Whether, from whom and when consent was sought and for what; whether  
this differed between treatment conditions.
Blinding 11a If done, who was blinded after assignment to sequences (eg, cluster level  
participants, individual level participants, those assessing outcomes) and 
how.
11b If relevant, description of the similarity of treatments.
Statistical methods 12a Statistical methods used to compare treatment conditions for primary and 
secondary outcomes including how time effects, clustering and repeated 
measures were taken into account.
12b Methods for additional analyses, such as subgroup analyses, sensitivity  
analyses, and adjusted analyses.
(Continued)
Supplementary materials 3: Checklist of information to include when reporting a stepped wedge cluster randomised 
trial (SW-CRT)
Topic Item no Checklist item Page no
Results
Participant flow  
(a diagram is  
strongly  
recommended)
13a For each treatment condition or allocated sequence, the numbers of clusters 
and participants who were assessed for eligibility, were randomly assigned,  
received intended treatments, and were analysed for the primary outcome 
(see separate SW-CRT flow chart).
13b For each treatment condition or allocated sequence, losses and  
exclusions for both clusters and participants with reasons.
Recruitment 14a Dates defining the steps, initiation of intervention, and deviations  
from planned dates. Dates defining recruitment and  follow-up for  
participants.
14b Why the trial ended or was stopped.
Baseline data 15 Baseline characteristics for the individual and cluster levels as applicable for 
each treatment condition or allocated sequence.
Numbers analysed 16 The number of observations and clusters included in each analysis for each 




17a For each primary and secondary outcome, results for each treatment  
condition, and the estimated effect size and its precision (such as 95%  
confidence interval); any correlations (or covariances) and time effects  
estimated in the analysis.
17b For binary outcomes, presentation of both absolute and relative effect sizes  
is recommended.
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and 
adjusted analyses, distinguishing prespecified from exploratory. 
Harms 19 Important harms or unintended effects in each treatment condition (for  
specific guidance see CONSORT for harms).
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if 
relevant, multiplicity of analyses.
Generalisability 21 Generalisability (external validity, applicability) of the trial findings.  
Generalisability to clusters or individual participants, or both  
(as relevant).
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and 
considering other relevant evidence.
Other information
Registration 23 Registration number and name of trial registry.
Protocol 24 Where the full trial protocol can be accessed, if available.




26 Whether the study was approved by a research ethics committee, with  
identification of the review committee(s). Justification for any waiver or  
modification of informed consent requirements.
This checklist has been taken from table 3 in BMJ 2018;363:k1614, as a standalone document for readers to print out or fill in electronically.
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